These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 21083245)
1. Human microdosing for the prediction of patient response. Henderson PT; Pan CX Bioanalysis; 2010 Mar; 2(3):373-6. PubMed ID: 21083245 [No Abstract] [Full Text] [Related]
2. Mass spectrometry imaging in drug development. Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173 [No Abstract] [Full Text] [Related]
5. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Garner RC Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253 [TBL] [Abstract][Full Text] [Related]
6. Microdosing in early lead discovery. Jekunen AP; Pauwels EK; Kairemo KJ Bioanalysis; 2010 Mar; 2(3):421-8. PubMed ID: 21083252 [TBL] [Abstract][Full Text] [Related]
7. New ultrasensitive detection technologies and techniques for use in microdosing studies. Lappin G; Wagner CC; Langer O; van de Merbel N Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172 [TBL] [Abstract][Full Text] [Related]
8. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Oosterhuis B Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246 [No Abstract] [Full Text] [Related]
9. Microdosing: current and the future. Lappin G Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258 [TBL] [Abstract][Full Text] [Related]
10. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals. Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588 [TBL] [Abstract][Full Text] [Related]
11. The utility of microdosing over the past 5 years. Lappin G; Garner RC Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326 [TBL] [Abstract][Full Text] [Related]
12. Commentary on 'Designs for dose-escalation trials with quantitative responses'. Senn S Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754 [No Abstract] [Full Text] [Related]
13. [Utility of a microdose study for drug discovery and development]. Yamaura Y Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):126-30. PubMed ID: 23470476 [No Abstract] [Full Text] [Related]
14. Microdosing Studies in Children: A US Regulatory Perspective. Roth-Cline M; Nelson RM Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312 [TBL] [Abstract][Full Text] [Related]
15. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures. Korfmacher W Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491 [No Abstract] [Full Text] [Related]
16. A reflection on fit-for-purpose metabolite investigation at different stages of drug development. Leclercq L Bioanalysis; 2014 Mar; 6(5):591-4. PubMed ID: 24620799 [No Abstract] [Full Text] [Related]
18. The i3+3 design for phase I clinical trials. Liu M; Wang SJ; Ji Y J Biopharm Stat; 2020 Mar; 30(2):294-304. PubMed ID: 31304864 [TBL] [Abstract][Full Text] [Related]
19. Clinical Drug Trials: The Path to the Patient. Diez Pascual C Methods Mol Biol; 2021; 2296():411-421. PubMed ID: 33977462 [TBL] [Abstract][Full Text] [Related]